A synthesised three-amino-acid peptide from the Khavinson bioregulator programme, directed at cartilage and connective tissue.

Why is cartilage hard to repair?

Because it has no blood supply. Most tissue has vessels threading through it delivering oxygen and materials; cartilage receives what it needs by slow diffusion from surrounding tissue instead, which makes repair far slower than in vascularised tissue.

How strong is the evidence?

Limited — preclinical and largely from the originating institute, with no regulatory approval anywhere.

Why does cartilage repair so poorly?

Because it has essentially no blood supply. Repair everywhere in the body depends on delivering oxygen, nutrients and repair cells to the damage, and blood vessels are how that happens. Nutrients reach cartilage only by seeping slowly through surrounding material, which sustains the tissue but cannot support rebuilding.

How does cartilage get nutrients at all?

Largely through movement. Compressing and releasing the tissue as you move pumps fluid in and out, which is much of how nutrients enter and waste leaves. The tissue is in effect fed by being used, which is one reason prolonged immobility affects it particularly.

Research Library›Bioregulators & Neuropeptides›Cartalax

Cartilage Bioregulator

Cartalax: The Peptide for Tissue With No Blood Supply

A three-amino-acid sequence aimed at cartilage — a tissue with no blood vessels running through it, which makes it uniquely bad at repairing itself.

5 min read·4 studies cited·Updated July 2026

Evidence level

Preclinical only — animal and cell studies

What this level means

Quick Reference

Sequence	Ala-Glu-Asp
Target tissue	Cartilage and connective tissue
Generation	Synthetic (second-generation)
Family	Khavinson bioregulators

What Is Cartalax?

Cartalax is a synthesised tripeptide from the Khavinson family, directed at cartilage and connective tissue. The name follows the family convention, from cartilage.

Why cartilage is difficult, in plain language: almost every tissue in the body has blood vessels threading through it, delivering oxygen and building materials and carrying waste away. Cartilage does not. It is avascular — no blood supply at all — and gets what it needs by slow diffusion from surrounding tissue, rather as a village at the end of a very long unpaved road receives supplies. Everything still arrives, just slowly and in small quantities. This is why cartilage damage heals so poorly compared with a cut on your skin: the repair crew can reach the site, but only at walking pace and carrying very little.

What the Research Examines

Published work examines Cartalax in connection with cartilage cell function and connective tissue maintenance, and it appears alongside collagen-focused research in the wider literature.

The evidence is preclinical and comes chiefly from the developing institute. There is no regulatory approval in any jurisdiction.

The Tissue With No Roads In

Almost every tissue in the body is threaded with blood vessels. Cartilage is not. It has essentially no blood supply at all, and that single fact explains nearly everything about it.

Repair anywhere in the body depends on delivery — bringing oxygen, nutrients and repair cells to the damage and taking waste away. Blood vessels are the road network that makes it possible. Cartilage is a district with no roads. Nutrients arrive only by seeping slowly through the surrounding material, which works for maintenance and is hopeless for rebuilding.

That is why cartilage injuries behave so differently from everything else. A cut heals in days and a broken bone knits in weeks, because both are well supplied. Damaged cartilage often simply stays damaged — not because the body does not want to repair it, but because it cannot get the materials to the site.

There is a second consequence worth knowing. Cartilage is squeezed and released as you move, and that pumping action is much of how nutrients get in and out at all. The tissue is fed by being used — an unusual arrangement, and one reason immobility affects it particularly.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed